CTOs on the Move

Doctor's Best

www.drbvitamins.com

 
We firmly believe in the integration of science research and traditional wisdom as the way that nutritional and herbal supplements will reach their exciting potential.   Founded in 1990 by a pioneering physician committed to science-based alternative health care, Doctor’s Best offers only the most important nutritional supplements. Careful research and precise formula development keeps us at the leading edge of quality, effectiveness, and innovation.   Containing the finest quality raw materials from around the world, Doctor’s Best supplements embody the best that traditional knowledge and current scientific research have to offer in the field of therapeutic nutrition. Countless hours have been spent analyzing ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.drbvitamins.com
  • 197 Avenida La Pata Suite A
    San Clemente, CA USA 92673
  • Phone: 949.498.3628

Executives

Name Title Contact Details

Similar Companies

Heat Biologics

Heat Biologics is a clinical-stage company focused on developing its proprietary ImPACT™ (Immune Pan-Antigen Cytotoxic Therapy), a fully allogeneic (“off-the-shelf”) cell-based immunotherapy for use in the treatment of a wide range of cancers.

Proginitor Cell Therapy

Proginitor Cell Therapy is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunitas Therapeutics

Immunitas Therapeutics is a single cell genomics-based drug discovery company.

Neuron23

Neuron23™ Inc. is an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases.

Aduro Biotech

Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro`s technology platforms, which are designed to harness the body`s natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro`s LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, this platform is being developed as a treatment for multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. Aduro`s STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. Aduro`s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms.